Motixafortide and Pembrolizumab Combined With Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
Clin. Cancer Res 2021 Jul 12;[EPub Ahead of Print], B Bockorny, T Macarulla, V Semenisty, E Borazanci, J Feliu, M Ponz-Sarvise, D Gutierrez Abad, P Oberstein, A Alistar, A Muñoz, R Geva, C Guillen-Ponce, M Salgado, A Peled, M Chaney, I Gliko-Kabir, L Shemesh-Darvish, D Ickowicz, E Sorani, S Kadosh, A Vainstein, M HidalgoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.